Genoskin will be showcasing its de-risking human skin platforms at booth #923 from May 15th to May 18th. Attendees will have the opportunity to learn about Genoskin’s non-clinical testing services, such as the ISR Platform® which uses immune profiling to assess Injection Site Reactions and local toxicity induced after subcutaneous injection of biologics.
Genoskin’s technology provides bio-stabilized and immunocompetent ex-vivo human skin from representative patient cohorts to elucidate efficacy and toxicity of drugs and vaccines.
Combined with advanced analytical technologies including next-generation transcriptomics, multiplexed proteomics and artificial intelligence, Genoskin generates actionable human data, significantly reducing the costs, length and risks associated with drug development, while replacing animal use.
During the PEGS conference, attendees can meet Genoskin’s representatives, including Yolaine Robitaille, Director of Business Development, Anna Falkowski, VP of Sales, and Kimbria Blake, Senior Study Director, who will be there to answer your questions and discuss how these innovative approaches are:
advancing and de-risking drug development
improving the reliability and reproducibility of nonclinical research
aligning with the FDA Modernization Act 2.0
Don’t miss out on this exciting opportunity to learn more about Genoskin’s innovative human skin models and technologies and meet the team. Swing by booth #923 and discover how Genoskin can help advance your nonclinical research project.
For more information about Genoskin and its services, please visit the company’s website at https://genoskin.com.